1. Home
  2. ALAB vs UTHR Comparison

ALAB vs UTHR Comparison

Compare ALAB & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALAB
    SELLHOLDBUYas of 2024 years ago
  • UTHR
    SELLHOLDBUYas of 4 days ago
  • Stock Information
  • Founded
  • ALAB 2017
  • UTHR 1996
  • Country
  • ALAB United States
  • UTHR United States
  • Employees
  • ALAB N/A
  • UTHR N/A
  • Industry
  • ALAB
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALAB
  • UTHR Health Care
  • Exchange
  • ALAB NYSE
  • UTHR Nasdaq
  • Market Cap
  • ALAB 14.2B
  • UTHR 14.4B
  • IPO Year
  • ALAB 2024
  • UTHR 1999
  • Fundamental
  • Price
  • ALAB $59.67
  • UTHR $307.34
  • Analyst Decision
  • ALAB Strong Buy
  • UTHR Buy
  • Analyst Count
  • ALAB 13
  • UTHR 12
  • Target Price
  • ALAB $111.23
  • UTHR $388.25
  • AVG Volume (30 Days)
  • ALAB 3.9M
  • UTHR 479.1K
  • Earning Date
  • ALAB 05-24-2025
  • UTHR 04-30-2025
  • Dividend Yield
  • ALAB N/A
  • UTHR N/A
  • EPS Growth
  • ALAB N/A
  • UTHR 24.38
  • EPS
  • ALAB N/A
  • UTHR 24.64
  • Revenue
  • ALAB $396,290,000.00
  • UTHR $2,877,400,000.00
  • Revenue This Year
  • ALAB $72.38
  • UTHR $11.07
  • Revenue Next Year
  • ALAB $31.75
  • UTHR $6.48
  • P/E Ratio
  • ALAB N/A
  • UTHR $12.51
  • Revenue Growth
  • ALAB 242.24
  • UTHR 23.63
  • 52 Week Low
  • ALAB $36.22
  • UTHR $221.53
  • 52 Week High
  • ALAB $147.39
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • ALAB N/A
  • UTHR 39.02
  • Support Level
  • ALAB N/A
  • UTHR $308.43
  • Resistance Level
  • ALAB N/A
  • UTHR $318.40
  • Average True Range (ATR)
  • ALAB 0.00
  • UTHR 9.26
  • MACD
  • ALAB 0.00
  • UTHR 1.20
  • Stochastic Oscillator
  • ALAB 0.00
  • UTHR 29.88

Stock Price Comparison Chart: ALAB vs UTHR

ALAB
UTHR
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025050100150200250300350400450ALAB VS UTHR

About ALAB ASTERA LABS INC

Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use